Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paliperidone (CCPC)
- Development stage
- Unknown
- Lead developer
- China Chemical & Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paliperidone (CCPC) is an oral extended-release formulation of the atypical antipsychotic paliperidone, developed by the China Chemical and Pharmaceutical Company (CCPC) in Taiwan. As the primary active metabolite of risperidone, paliperidone functions as a central dopamine D2 receptor antagonist and a serotonin 5-HT2A receptor antagonist. It also exhibits antagonistic activity at alpha-1 and alpha-2 adrenergic receptors and H1 histaminergic receptors. This specific formulation is designed to provide a controlled release of the medication over a 24-hour period, reducing the peak-to-trough fluctuations associated with immediate-release antipsychotics. It is approved in Taiwan for the treatment of schizophrenia and schizoaffective disorder.
- Brand names
- 佩里波持續性藥效錠Pei Li Bo
- Other names
- Paliperidone extended-release tabletPaliperidone ER
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)ADRA2A (α2A)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on Paliperidone (CCPC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paliperidone (CCPC).